Last updated on March 2018

Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic Subjects

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Acromegaly
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Men or women aged 18 years
  • Diagnosed with acromegaly
  • Receiving treatment with ATG 120 mg at extended dosing intervals (> 4 weeks) for at least six months before the study visit.
  • Assay data (blood GH and IGF-1 levels) from immediately before the study visit (performed at least six months after starting the treatment) is available.
  • Able to sign the informed consent form for study participation.

Exclusion Criteria:

  • Received radiation therapy treatment in the last six months.
  • Active participation in another clinical study.
  • Physical or mental disorders that, in the investigator's opinion, could affect their ability to sign the informed consent form.
  • Pregnancy or breastfeeding for female patients.
  • No data in their medical records on the treatment start date for ATG 120 mg at extended dosing intervals or on changes to the schedule of administration over the last six months.

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.